This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fortuny, J. Articles by Boffetta, P. Search for Related Content PubMed PubMed Citation Articles by Fortuny, J. Articles by Boffetta, P. Related Collections Epidemiology Epidemiology: Classical Epidemiology

Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH

¹ Epidemiology, Municipal Institute of Medical Research, Barcelona, Catalonia, Spain; ² Epidemiology and Cancer Registry, Catalan Institute of Oncology, Barcelona, Catalonia, Spain; ³ Division of Epidemiology, German Cancer Research Center, Heidelberg, Germany; ⁴ Unit of Biological Haematology, Hematology, Dijon University Hospital, Dijon, France; ⁵ Institute of Occupational Medicine, University of Cagliari, Cagliari, Italy; ⁶ Department of Public Health, Public Health University College Dublin, Dublin, Ireland; ⁷ Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic; ⁸ Department of Pathology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland; ⁹ IARC, Lyon, France; and ¹⁰ Servei d'Anatomia Patològica, Hospital Verge de la Cinta, Tortosa, Catalonia, Spain

Requests for reprints: Silvia de Sanjosé, Servei d'Epidemiologia i Registre del Càncer, Institut Català d'Oncologia, Gran Via Km 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain. Phone: 34-932607812; Fax: 34-932607787. E-mail: s.sanjose{at}ico.scs.es

Background: Statins, drugs used to treat dyslipidemia, may have anticancer properties. We have evaluated lymphoma risk associated with regular statin use in an international case-control study.

Methods: This case-control study included 2,362 cases of incident B- and T-cell lymphoma from Czech Republic, France, Germany, Ireland, Italy, and Spain and 2,206 hospital or population controls. Information on drug use, diagnosis at admission (for hospital controls), and putative risk factors for lymphoma was collected with personal interviews. Hospital controls admitted for diseases possibly entailing use of statins were excluded from the analysis.

Results: The odds ratio for regular statin use was 0.61 (95% confidence interval, 0.45-0.84); all major lymphoma subtypes showed similarly decreased risks. Decreased risks were observed in all centers. Duration of statin use was not associated with a greater reduction in the risk of lymphoma. Use of other lipid lowering drugs, such as fibrates, did not significantly modify the risk of lymphoma (odds ratio, 0.75; 95% confidence interval, 0.44-1.27).

Conclusion: Statin use was associated with an important reduction in lymphoma risk, adding to the growing evidence of anticancer properties of this group of drugs. These results are reassuring for the increasing number of patients taking statins on a regular basis. (Cancer Epidemiol Biomarkers Prev 2006;15(5):921–5)

This article has been cited by other articles:

				P. Boffetta, O. v. d. Hel, A. Kricker, A. Nieters, S. d. Sanjose, M. Maynadie, P. L. Cocco, A. Staines, N. Becker, R. Font, et al. Exposure to ultraviolet radiation and risk of malignant lymphoma and multiple myeloma--a multicentre European case-control study Int. J. Epidemiol., May 29, 2008; (2008) dyn092v1. [Abstract] [Full Text] [PDF]

				P. J. Hayden, P. Tewari, D. W. Morris, A. Staines, D. Crowley, A. Nieters, N. Becker, S. de Sanjose, L. Foretova, M. Maynadie, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma Hum. Mol. Genet., December 15, 2007; 16(24): 3117 - 3127. [Abstract] [Full Text] [PDF]

				U. Lim, T. Gayles, H. A. Katki, R. Stolzenberg-Solomon, S. J. Weinstein, P. Pietinen, P. R. Taylor, J. Virtamo, and D. Albanes Serum High-Density Lipoprotein Cholesterol and Risk of Non-Hodgkin Lymphoma Cancer Res., June 1, 2007; 67(11): 5569 - 5574. [Abstract] [Full Text] [PDF]

				B. von Tresckow, E. P. von Strandmann, S. Sasse, S. Tawadros, A. Engert, and H. P. Hansen Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo Haematologica, May 1, 2007; 92(5): 682 - 685. [Abstract] [Full Text] [PDF]